tbuckley/cabot-search huggingface dataset:
Lead Exposure and Intelligence in 7-Year-Old Children: The Yugoslavia Prospective Study
Authors: Gail A. Wasserman, Xinhua Liu, Nancy J. Lolacono, Pam Factor-Litvak, Jennie K. Kline, Dusan Popovac, Nada Morina, Aida Musabegovic, Nait Vrenezi, Sabahate Capuni-Paracka, Vojkan Lekic, Emine Preteni-Redjepi, Suzana Hadzialjevic, Vesna Slavkovich, Joseph H. Graziano
Journal: Environmental Health Perspectives (1997)

For a prospective study of lead exposure and early development, we recruited pregnant women from a lead smelter town and from an unexposed town in Yugoslavia and followed their children through 7 years of age. In this paper we consider associations between lifetime lead exposure, estimated by the area under the blood lead (BPb) versus time curve (AUC7), and intelligence, with particular concern for identifying lead's behavioral signature. The Wechsler Intelligence Scales for Children-Version III (WISC-III) was administered to 309 7-year-old children, 261 of whom had complete data on intelligence, blood lead, and relevant sociodemographic covariates (i.e., Home Observation for the Measurement of the Environment (HOME), birth weight, gender, sibship size, and maternal age, ethnicity, intelligence, and education). These showed anticipated associations with 7-year intelligence, explaining 41-4% of the variance in Full Scale, Performance, and Verbal IQ. Before covariate adjustment, AUC7 was unrelated to intelligence; after adjustment, AUC7 explained a significant 2.8%-4.2% of the variance in IQ. After adjustment, a change in lifetime BPb from 10 to 30 micro/dl related to an estimated decrease of 4.3 Full Scale IQ points; estimated decreases for Verbal and Performance IQ were 3.4 and 4.5 points, respectively. AUC7 was significantly and negatively related to three WISC-III factor scores: Freedom from Distractibility, Perceptual Organization, and Verbal Comprehension; the association with Perceptual Organization was the strongest. Consistent with previous studies, the IQ/lead association is small relative to more powerful social factors. Findings offer support for lead's behavioral signature; perceptual-motor skills are significantly more sensitive to lead exposure than are the language-related aspects of intelligence.
“Folic Acid”: Pteroylglutamic Acid and Related Substances
Authors: Frederick Sargent
Journal: New England Journal of Medicine (1947)

THE discovery, isolation, synthesis and clinical use of a new member of the vitamin B complex called "pteroylglutamic acid" can be attributed to the combined efforts of many different investigative groups. During the past sixteen years this substance has ascended from bacteria to chick, from chick to rat, from rat to monkey and from monkey to man as an essential nutrient. During its ascent, but before its isolation and synthesis, this substance picked up many names (Table 1), for each group of investigators that studied it did not then realize that their material was quite similar to that described by . . .
1A: Drug resistance in H. pylori from basic mechanisms to clinical outcome
Authors: A Mclaren, C Donnelly, R Adamek, S Suerbaum, B Pfaffenbach, M Wegener, U Peitz, A Nusch, B Tillenburg, M Stoltei, G Borsch, J Labenz, E De Koster, A Cozzoli, C Jonas, R Ntounda, J Butzler, M Deltenre
Journal: Gut (1996)

Antibiotic resistance is a major cause of treatment failure in eradicating H. pylori and subsequent relapse of disease symptoms.Cost considerations have limited the number of studies comparing resistance pre and post treat- ments, and monitoring effect of resistance pre-treatment on eradication.What is the degree of resistance determining treatment failure?This study was performed to measure three parameters 1) Minimum inhibitory concentration (MIC) of metronidazole (met) and clarithromycin (clar) against resistant strains 2) the numbers of resistant organisms within the total populations and 3) their stability, both in numbers and sensitivity over a range of subcultures. 10strains comprising of 9 freshly obtained clinical isolates and one laboratory generated resistant strain were studied. 3clinical strains were found to be resistant to both clar and met, only 2 of the clinical isolates were sensitive.MICs against met ranged from 31-250 ,ug/ml for the resistant isolates, 2 ,ug/ml against the sensitive.Against clar resistant strains,MIC ranged from 31-250,ug/ml, as opposed to 0.03-0.13itg/ml for sensitive isolates.One strain showed intermediate susceptibility, MIC 2 ,ug/ml.There was wide variation in the numbers of organisms found to be resistant in the populations, ranging from 1 in 105 to totally resistant.Sensitive strains acquired resistance in < 1 in 108.The numbers of organisms found to be resistant was stable over 10 sub-cultures for 8 isolates, but an increase in clar susceptibility was found in the intermediate strain and 1 isolate.These studies have shown there are not just drug resistant and sensitive H. pylori strains.Emergence of resistance may not always be observed in strains that appear resistant.The numbers of resistant organisms within a population may be as important as the susceptibility of the isolates to antibiotics.
PAROXYSMAL HAEMOGLOBINURIA
Authors: E. Emrys-Roberts
Journal: BMJ (1915)

Since then he had been oni a strict diet.For the last fortniight he had complained of great lassitude.His eyesight had become bad.He lha'd 'weiglied ll-st.previously.On admission his weight was 8st.8lb.; lie was rather drowsy; his breath smelt of acetone.There was a small haemorrhage in the riglht retina, with some retinitis.The ferric chloride reactioni was strotigly positive.A diet containing 113 grams carbohydrate was giveln anid sodiuni bicarbonate in large doses by the mouth and rectum (78 grams on January 7th).On January 9th ammonia N was 4.4 grams, index 13.6 per cent.He passed about 8 oz.(227 grams) sugar daily.On January 11th the urine was, fainitly alkalinie. .On January 13th ammonia N was 2.6 grams.l He was nlow walking about the ward.The large doses of sodiuni bicarbonate were still continued.On January 22nd the patienit's legs began to be oedematous.The sodium bicarbonate was diminished to 51 grams for three days, and it was theni increased again to the previous amount.The oedlema disappeared in t-wenty-four hours.On January 26th a normal full diet was given, with porridge and milk ad lib.. On Januiary 29th, 2 a.m., the patient suddenly had an attack of abdominal pain.He become delirious.He redained conscious ness, and remained conscious right till his death, the next morning at 4 o'clock.NVhile in hospital the alveolar CO2 showed large variations-that is, betweeni 2 anid 5 per cent.Post Mortemu.-Lipaemia,due to a finely divided suspension of fat.General wastinig.Atrophied pancreas.METHODS OF ANALYSIS EMPLOYED.Sugar.-Benedict's methodl.Aiwnoida.-Bvformol titrationi.Am)imonia Inldex (that is, the ratio betweeni the amimonia nitrogen anid total nitrogen).-Thetotal nitrogeii was calculated from the amoloutnt of urea, determined hy Dupres's nmethod, assuminig that the urea niitrogen was always 96 per cent. of the total niitrogen.This is approxinmately the case unlder ordinary conditions of diet, and the results are accurate enough for elinical purposes.The Dupr6s method is much simpler than Bijedlahl's, an-d takes less time to perform.REFEIWNcES.
Births in Mount Carmel Mercy Hospital
Journal: JAMA (1941)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Reducing pills and digitalis intoxication
Journal: JAMA (1968)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Journals JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2024 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Notes on the Medical Treatment of Disease. For Students and Young Practitioners of Medicine.
Journal: JAMA (1924)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Real-world patterns and predictors of first-line maintenance use among patients with newly diagnosed advanced ovarian cancer: Is there an opportunity for change?
Authors: Jinan Liu, Premal H. Thaker, Janvi Sah, Eric M Maiese, Oscar Bee, Jean Hurteau, John Chan
Journal: Journal of Clinical Oncology (2021)

294 Background: With the advent of poly(ADP-ribose) polymerase inhibitors (PARPi), options for first-line (1L) maintenance therapy in ovarian cancer (OC) have evolved in the US. This study described the use of 1L maintenance and assessed predictors of 1L maintenance use among PARPi-eligible patients (pts) with OC in a real-world setting. Methods: This retrospective cohort study included pts with newly diagnosed stage III/IV epithelial OC who received 6–9 cycles of 1L platinum-based chemotherapy (PBC) and primary or interval debulking surgery following neoadjuvant chemotherapy between Jan 1, 2016, and Feb 29, 2020, from the nationwide Flatiron Health electronic health record–derived deidentified database. The end of the last cycle of 1L PBC was defined as the index date. Those pts who started second-line chemotherapy within 2 months of the index date were excluded. Logistic regression was used to analyze variables with regard to 1L maintenance use. Results: In total, 463 pts were included; 21% received maintenance therapy, 79% received active surveillance. Baseline characteristics are shown in the table. Overall maintenance therapy use increased over the study period, from 7.7% to 37.7%. Pts with BRCA wild type were significantly less likely to receive maintenance therapy (odds ratio [OR]: 0.30; 95% CI, 0.16–0.59) than pts with BRCA mutation. Pts treated in 2018 (OR: 2.73; 95% CI, 1.25–5.98) and 2019 (OR: 8.78; 95% CI, 4.15–18.55) were significantly more likely to receive maintenance therapy than pts treated in 2017. Age, race, practice type, ECOG score, and residual disease status were not significant predictors of 1L maintenance use. Conclusions: Nearly 40% of pts with advanced stage OC received upfront maintenance therapy with an increasing trend over time, particularly in those with biomarker guidance. Research is warranted toward addressing barriers to the appropriate use of maintenance therapy.[Table: see text]
The Vitamins.
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Early assessment of therapy response in small cell lung cancer via longitudinal ctDNA analysis.
Authors: John F. Palma, Corinna Woestmann, Sylvie McNamara, Bernd Hinzmann, Sebastian Fröhler, Hans-Peter Adams, Mirjam Feldkamp, Sandra Siemann, Maria Lange, Anja Blüher, Stephanie Yaung, Liu Xi, Nalin Tikoo, Aarthi Balasubramanyam, Christine Ju, Amrita Pati, Birgit Wehnl, Thomas Muley, Xiaoju Max Ma, Felix Herth
Journal: Journal of Clinical Oncology (2018)

8577 Background: From the prospective, observational German Lung Cancer Multi-Marker Study we selected the first 72 consecutive small-cell lung cancer (SCLC) patients, UICC-stage IIIB/IV, where plasma samples were available prior to start of therapy, and prior to the second cycle of chemotherapy, and prior to third cycle. We hypothesized that assessment of the level of ctDNA after starting therapy relates to treatment effect and prognosis. Methods: We employed AVENIO ctDNA Surveillance Kit, a 197-gene NGS assay, which allowed us to perform longitudinal ctDNA analysis and measure the mutant molecules per milliliter-of-plasma (MMPM), which quantifies ctDNA over all variants of all sequenced genomic regions. All extracted cfDNA samples were processed and sequenced in order of date of blood draw. Results: At baseline (b0), we identified variants in all (72/72) subjects to enable ctDNA monitoring. Using serial liquid biopsies from each subject, the mean MMPM at post-first treatment cycle (p1) and the mean MMPM at post-second treatment cycle (p2) were analyzed. We tested a Continuous Responder algorithm, defined by a continuous drop in ctDNA levels represented by mean MMPM reduction over time (p2 < p1 < b0), to a mean MMPM below 20 at p2. As a result, continuous responders 26/72 were associated with a better therapy response OS HR = 1.9 (95% CI 1.1 – 3.2, log-rank P = 0.015). The continuous responders demonstrated a median survival benefit of 4.4 months over the poor responders. Neither gender, nor age, nor ECOG, nor stage were predictors of response in the models. Conclusions: An early assessment of treatment effect can be measured by mutant molecule counts in the plasma. A decrease in post-treatment ctDNA levels was associated with better prognosis in advanced SCLC.
Presently Known Distribution of Furocoumarins (Psoralens) in Plants
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Value of imprint cytology for ultrasound-guided transthoracic core biopsy
Authors: W-Y. Liao, J-S. Jerng, K-Y. Chen, Y-L. Chang, P-C. Yang, S-H. Kuo
Journal: European Respiratory Journal (2004)

The aim of this study was to investigate the possible additional diagnostic information provided by imprint cytology when performing ultrasound-guided transthoracic core biopsy and to evaluate whether it could optimise the biopsy procedure. A total of 155 transthoracic core biopsies with touch imprint smears were performed under ultrasound guidance, with 127 malignant and 28 benign lesions. The imprint smears were stained using Riu's method and interpreted by a cytopathologist. These were compared with the histopathology of core biopsy specimens and the final diagnosis of malignant versus benign disease. The overall diagnostic accuracy of imprint cytology was 94% (146 out of 155). Histopathological analysis showed an overall accuracy of 94% (146 out of 155), with a sensitivity of 94% (119 out of 127) and negative predictive value of 79% (27 out of 34). The combination of these two methodologies had an increased overall accuracy and negative predictive value of 98% (152 out of 155) and 90% (28 out of 31), respectively. The results of imprint cytology and histopathology were in agreement in 143 patients (92%). In conclusion, imprint cytology of ultrasound-guided transthoracic core biopsy is a sensitive procedure for diagnosing peripheral thoracic lesions, and it may increase the diagnostic accuracy and cancer negative prediction of biopsy alone. With an on-site approach, imprint cytology may help to assess the adequacy of biopsy specimens and optimise the biopsy procedure.
A33 Phase I Trial of in Situ Vaccination with Autologous CCL21-Modified Dendritic Cells (CCL21-DC) Combined with Pembrolizumab for Advanced NSCLC
Authors: B. Liu, A. Lisberg, R. Salehi-Rad, J.M. Lee, L.M. Tran, K. Krysan, R. Li, R.J. Lim, C. Dumitras, Z. Jing, F. Abtin, R.D. Suh, S.J. Genshaft, S. Oh, D.R. Aberle, L.E. Winter, S. Sharma, D. Elashoff, E.B. Garon, S.M. Dubinett
Journal: Journal of Thoracic Oncology (2020)
Intravascular capacitometry: A new method to image both morphology and composition of the coronary wall by using a special intracoronary catheter Leonidas D. Diamantopoulos, Glenn Van Langenhove, David Folley, Pim De Feyter, Marcel Van de Brand, Patrick W. Serruys. Interventional Cardiology Dept, THORAXCENTER, ROTTERDAM, The Netherlands
Journal: Journal of the American College of Cardiology (2001)
Abstract O.58: Medium-term Outcomes of Coronary Artery Aneurysms after Kawasaki Disease: A Study from the North American Kawasaki Disease Registry
Authors: Brian W McCrindle, Cedric Manlhiot, Kristen Sexson, Pei-Ni Jone, Mathew Mathew, Kambiz Norozi, Kevin C Harris, Alana Hughes, Anne Ferris, Frederic Dallaire, Andrew M Crean, Nagib Dahdah
Journal: Circulation (2015)

Background: One of the main impediments to conceiving and planning studies in children with coronary artery aneurysms (CAA) after Kawasaki disease (KD) is the lack of normative data regarding the prevalence of outcomes over time and risk factors. Methods: The North American Kawasaki Disease Registry was used to determine the prevalence of multiple clinically important outcomes of CAA after KD. All analyses were stratified by severity of CAA (small CAA with z-score = 2.5-5, medium with z-score = 5-10 and giant with z-score &gt;10). All analyses were performed using non-parametric survival analysis. Results: n=621 patients submitted to the Registry had complete follow-up data and were included in the analysis (280 [45%] small CAA, 139 [22%] medium and 202 [33%] giant). Time-related freedom from multiple outcomes stratified by type of CAA are reported in the Table. Reduction in z-scores was strongly associated with the initial size of the lesion, with smaller lesions being more likely to decrease to a normal dimension over time. Thrombosis and stenosis were infrequent in patients without giant CAA. For those patients with giant CAA, the risk of thrombosis, myocardial infarction, angiographically-confirmed stenosis and revascularization was substantial and persisted up to 10 years after diagnosis. In addition to larger luminal diameter, other factors associated with increased risk of adverse outcomes included larger CAA longitudinal area and complex CAA (vs. isolated lesions). Conclusions: Only patients with giant CAA are at substantial risk of adverse clinical outcomes; future trials of pharmacological therapy targeting thrombosis and stenosis risk should focus on these patients.